# NCT02252172 (NCT02252172)

> Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02252172
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Janssen Research & Development, LLC
- Conditions: Multiple Myeloma
- Interventions: Daratumumab IV; Lenalidomide; Dexamethasone; Daratumumab SC
- Enrollment: 737
- Primary outcome: Progression-free Survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 123
- YouTube: 65
- Podcasts: 25
- X videos: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct02252172

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02252172", "email": "<work email>"}; the inbox owner confirms by the emailed link.